LineaRx will present its Linea™ IVT platform - a combination of an enzymatically produced DNA template (Linea™ DNA IVT template) coupled with a next-generation RNA polymerase (Linea™ RNAP) - as a ...
RNA-based therapeutics are transforming medicine, but scaling production efficiently remains a challenge, particularly the cost-intensive in vitro transcription (IVT) step. Join this webinar to ...
In an era where viral outbreaks can escalate into global pandemics with alarming speed, the ability to quickly develop new vaccines has become crucial. However, the speed of vaccine production is ...
With viral outbreaks spreading more quickly, faster responses and quicker development of new vaccines has become crucial. However, production of the mRNA used in vaccines is hindered by its production ...
From global vaccines to personalized cancer therapies, mRNA is being considered across several clinical applications, which ultimately creates varying requirements in terms of production scale and ...
Learn from the MHRA about evolving CMC expectations, submission criteria, and initiatives for streamlining approval routes for mRNA platforms. Continuous processing: Optimizing efficiency & ...
The success of the mRNA-based vaccines against SARS-CoV-2 merely hint at the healthcare implications of mRNA technology. More mRNA-based vaccines are in the works, as are mRNA-based therapeutics for ...
STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced its participation at upcoming mRNA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results